دورية أكاديمية
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
العنوان: | High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. |
---|---|
المؤلفون: | Garcha HK; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada., Nawar N; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada., Sorger H; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Erdogan F; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada., Aung MMK; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Sedighi A; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada., Manaswiyoungkul P; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., Schönefeldt S; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Pölöske D; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., Neubauer HA; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Mustjoki SM; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014 Helsinki, Finland.; Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, 00014 Helsinki, Finland., Herling M; Department of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, 04109 Leipzig, Germany., de Araujo ED; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada., Moriggl R; Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria., Gunning PT; Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada. |
المصدر: | Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2022 Oct 26; Vol. 15 (11). Date of Electronic Publication: 2022 Oct 26. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, c2004- |
مستخلص: | NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, including T-cell lymphomas. This study represents exploratory findings of HDAC6 inhibition in NKTCL and γδ T-NHL through a second-generation inhibitor NN-429. With nanomolar in vitro HDAC6 potency and high in vitro and in cellulo selectivity for HDAC6, NN-429 also exhibited long residence time and improved pharmacokinetic properties in contrast to older generation inhibitors. Following unique selective cytotoxicity towards γδ T-NHL and NKTCL, NN-429 demonstrated a synergistic relationship with the clinical agent etoposide and potential synergies with doxorubicin, cytarabine, and SNS-032 in these disease models, opening an avenue for combination treatment strategies. |
References: | ACS Chem Biol. 2015 Aug 21;10(8):1797-804. (PMID: 26006698) Cancers (Basel). 2021 Dec 09;13(24):. (PMID: 34944832) Hum Pathol. 2018 Apr;74:5-16. (PMID: 29337025) Cancer Discov. 2017 Apr;7(4):369-379. (PMID: 28122867) Drug Saf. 2019 Feb;42(2):235-245. (PMID: 30649740) Oncotarget. 2017 Jan 10;8(2):2694-2707. (PMID: 27926524) PLoS Comput Biol. 2020 Feb 3;16(2):e1007604. (PMID: 32012154) J Hematol Oncol. 2018 Dec 20;11(1):140. (PMID: 30567593) Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. (PMID: 20057044) Nat Rev Cancer. 2017 May;17(5):286-301. (PMID: 28338065) Expert Rev Anticancer Ther. 2010 Jul;10(7):997-1008. (PMID: 20645688) Curr Med Chem. 2002 Sep;9(17):1631-53. (PMID: 12171558) Nat Rev Cancer. 2010 Feb;10(2):130-7. (PMID: 20094047) J Biomed Biotechnol. 2011;2011:875824. (PMID: 21076528) Cancer Res. 2018 Jul 1;78(13):3709-3717. (PMID: 29760044) J Clin Oncol. 2008 Sep 1;26(25):4124-30. (PMID: 18626005) Acta Crystallogr D Biol Crystallogr. 2013 Apr;69(Pt 4):625-34. (PMID: 23519671) Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):381-90. (PMID: 22505258) Lancet Oncol. 2016 Nov;17(11):1569-1578. (PMID: 27646843) Bioinformatics. 2020 Apr 15;36(8):2645. (PMID: 32118251) Trends Pharmacol Sci. 2014 Oct;35(10):501-9. (PMID: 25234862) Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94. (PMID: 12677000) J Med Chem. 2021 Mar 11;64(5):2691-2704. (PMID: 33576627) PLoS Med. 2019 Jul 9;16(7):e1002851. (PMID: 31287813) Clin Cancer Res. 2021 Jul 1;27(13):3584-3594. (PMID: 33947698) Front Oncol. 2021 Sep 06;11:696512. (PMID: 34552864) Nat Biotechnol. 2007 Jan;25(1):84-90. (PMID: 17211407) ACS Omega. 2021 Aug 20;6(34):21843-21849. (PMID: 34497879) J Pharm Biomed Anal. 2019 Jan 5;162:60-65. (PMID: 30223143) J Cell Sci. 2007 Apr 15;120(Pt 8):1469-79. (PMID: 17389687) Nat Biotechnol. 2012 Jul 10;30(7):679-92. (PMID: 22781697) Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002) Curr Org Chem. 2019;23(9):978-993. (PMID: 32565717) PLoS One. 2017 Mar 6;12(3):e0173507. (PMID: 28264055) Blood. 2004 Jul 15;104(2):328-35. (PMID: 15044256) Methods Mol Biol. 2019;1888:45-71. (PMID: 30519940) Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67. (PMID: 22505256) J Med Chem. 2020 Nov 12;63(21):12460-12484. (PMID: 32608981) Oncogene. 2007 Aug 13;26(37):5468-76. (PMID: 17694087) Mol Cell Biol. 2008 Mar;28(5):1688-701. (PMID: 18180281) Blood. 2003 Dec 15;102(13):4261-9. (PMID: 12907441) J Med Chem. 2022 Feb 24;65(4):3193-3217. (PMID: 35119267) Psychopharmacology (Berl). 2020 Jul;237(7):2139-2149. (PMID: 32388618) J Med Chem. 2021 Jun 24;64(12):8486-8509. (PMID: 34101461) Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. (PMID: 27713375) Arthritis Res Ther. 2020 Jul 25;22(1):176. (PMID: 32711562) Br J Pharmacol. 2020 Nov;177(22):5096-5113. (PMID: 33460073) Sci Transl Med. 2015 Jun 24;7(293):293ra102. (PMID: 26109102) Sci Rep. 2014 Jun 05;4:5193. (PMID: 24898935) Eur J Med Chem. 2020 Sep 1;201:112411. (PMID: 32615502) J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. (PMID: 19461840) Nature. 2002 May 23;417(6887):455-8. (PMID: 12024216) Oncotarget. 2017 May 24;8(34):56747-56757. (PMID: 28915627) Mol Cell Biol. 2005 Apr;25(8):2873-84. (PMID: 15798178) Mol Neurodegener. 2013 Jan 29;8:7. (PMID: 23356410) J Med Chem. 2007 Nov 15;50(23):5720-6. (PMID: 17958342) J Appl Crystallogr. 2009 Aug 1;42(Pt 4):607-615. (PMID: 19649324) Ann Oncol. 2009 Jan;20(1):121-8. (PMID: 18684695) Nat Commun. 2018 Feb 15;9(1):697. (PMID: 29449575) Bioorg Med Chem Lett. 2008 May 1;18(9):2809-12. (PMID: 18430569) |
معلومات مُعتمدة: | I 4157 Austria FWF_ Austrian Science Fund FWF; I 4218 Austria FWF_ Austrian Science Fund FWF; P30 GM124165 United States GM NIGMS NIH HHS; S10 OD021527 United States OD NIH HHS |
فهرسة مساهمة: | Keywords: HDAC6; NKTCL; combination treatment; small molecule inhibitor; synergy |
تواريخ الأحداث: | Date Created: 20221110 Latest Revision: 20240327 |
رمز التحديث: | 20240327 |
مُعرف محوري في PubMed: | PMC9692247 |
DOI: | 10.3390/ph15111321 |
PMID: | 36355493 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1424-8247 |
---|---|
DOI: | 10.3390/ph15111321 |